Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal
The move marks a sign the company is bulking up on rare disease medicines as its older multiple sclerosis drugs face tepid demand due to rising competition.
Source link
- Maggot infestations and wounds that never heal for Gaza’s malnourished
- Malta to recognize Palestine as state ‘when the time is right’
